44102 Risankizumab Efficacy for Moderate-to-Severe Plaque Psoriasis over 256 Weeks in Patients with Prior Biologic Treatments - 25/09/23
Doi : 10.1016/j.jaad.2023.07.333
Chih-Ho Hong
University of British Columbia, Department of Dermatology and Skin Science and Probity Medical Research, Surrey, BC, Canada
Melinda Gooderham
SKiN Centre for Dermatology, Queen’s University, and Probity Medical Research Inc., Peterborough, ON, Canada
Georgios Kokolakis
Psoriasis Research and Treatment Centre, Charité – Universitätsmedizin Berlin, Berlin, Germany, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Germany
Le texte complet de cet article est disponible en PDF.
| Commercial Support: AbbVie Inc, participated in the study design; study research; collection, analysis and interpretation of data; and writing, reviewing, and approving of this abstract for submission. AbbVie funded the research for this study and provided writing support fo. |
© 2023
Publié par Elsevier Masson SAS.
Vol 89 - N° 3S
P. AB82 - septembre 2023 Retour au numéro
Article précédent
- 42243 RIAM regulates T cell migration and activation in melanoma
- Sasitorn Yenyuwadee, Konstantinos Aliazis, Anthos Christofides, Halil-Ibrahim Aksoylar, Rinku Pal, Vassiliki A. Boussiotis
- 43067 Risankizumab for the treatment of moderate-to-severe psoriasis: Real-world data from the Czech Republic BIOREP Registry
- Martina Kojanova, Jorga Fialova, Petra Cetkovska, Spyridon Gkalpakiotis, Alena Machovcova, Petr Arenberger, Jiri Stork, Tomas Dolezal, Daniela Strosova
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?